Boston Scientific’s drug-coated balloon meets one-year endpoint

Boston Scientific’s clinical trial investigating its Agent drug-coated balloon has met its primary endpoint in a trial evaluating its safety and effectiveness as a treatment for coronary in-stent restenosis.